![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BCL2L11 |
Gene summary for BCL2L11 |
![]() |
Gene information | Species | Human | Gene symbol | BCL2L11 | Gene ID | 10018 |
Gene name | BCL2 like 11 | |
Gene Alias | BAM | |
Cytomap | 2q13 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O43521 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10018 | BCL2L11 | LZE4T | Human | Esophagus | ESCC | 3.54e-08 | 6.85e-02 | 0.0811 |
10018 | BCL2L11 | LZE7T | Human | Esophagus | ESCC | 2.17e-03 | 2.85e-01 | 0.0667 |
10018 | BCL2L11 | LZE20T | Human | Esophagus | ESCC | 1.42e-03 | 2.96e-02 | 0.0662 |
10018 | BCL2L11 | LZE24T | Human | Esophagus | ESCC | 7.30e-11 | 3.56e-01 | 0.0596 |
10018 | BCL2L11 | P1T-E | Human | Esophagus | ESCC | 1.60e-07 | 4.35e-01 | 0.0875 |
10018 | BCL2L11 | P2T-E | Human | Esophagus | ESCC | 3.35e-09 | 2.27e-01 | 0.1177 |
10018 | BCL2L11 | P4T-E | Human | Esophagus | ESCC | 8.98e-22 | 6.94e-01 | 0.1323 |
10018 | BCL2L11 | P5T-E | Human | Esophagus | ESCC | 5.37e-18 | 2.83e-02 | 0.1327 |
10018 | BCL2L11 | P8T-E | Human | Esophagus | ESCC | 4.11e-13 | 1.02e-01 | 0.0889 |
10018 | BCL2L11 | P9T-E | Human | Esophagus | ESCC | 1.19e-11 | 3.16e-01 | 0.1131 |
10018 | BCL2L11 | P10T-E | Human | Esophagus | ESCC | 5.53e-10 | 3.33e-01 | 0.116 |
10018 | BCL2L11 | P11T-E | Human | Esophagus | ESCC | 1.08e-08 | 5.96e-01 | 0.1426 |
10018 | BCL2L11 | P12T-E | Human | Esophagus | ESCC | 4.65e-11 | 3.09e-01 | 0.1122 |
10018 | BCL2L11 | P15T-E | Human | Esophagus | ESCC | 4.29e-21 | 5.08e-01 | 0.1149 |
10018 | BCL2L11 | P16T-E | Human | Esophagus | ESCC | 3.96e-14 | 7.49e-02 | 0.1153 |
10018 | BCL2L11 | P20T-E | Human | Esophagus | ESCC | 3.32e-05 | 1.85e-01 | 0.1124 |
10018 | BCL2L11 | P21T-E | Human | Esophagus | ESCC | 1.83e-15 | 2.72e-01 | 0.1617 |
10018 | BCL2L11 | P22T-E | Human | Esophagus | ESCC | 1.08e-16 | 7.51e-04 | 0.1236 |
10018 | BCL2L11 | P23T-E | Human | Esophagus | ESCC | 1.23e-17 | 6.04e-01 | 0.108 |
10018 | BCL2L11 | P24T-E | Human | Esophagus | ESCC | 5.90e-09 | 1.51e-01 | 0.1287 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
GO:0034976111 | Esophagus | ESCC | response to endoplasmic reticulum stress | 192/8552 | 256/18723 | 7.15e-22 | 1.30e-19 | 192 |
GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
GO:0006839110 | Esophagus | ESCC | mitochondrial transport | 187/8552 | 254/18723 | 8.35e-20 | 9.81e-18 | 187 |
GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
GO:0035966111 | Esophagus | ESCC | response to topologically incorrect protein | 125/8552 | 159/18723 | 1.44e-17 | 1.27e-15 | 125 |
GO:2001242111 | Esophagus | ESCC | regulation of intrinsic apoptotic signaling pathway | 128/8552 | 164/18723 | 1.75e-17 | 1.50e-15 | 128 |
GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
GO:0097191111 | Esophagus | ESCC | extrinsic apoptotic signaling pathway | 159/8552 | 219/18723 | 4.12e-16 | 2.94e-14 | 159 |
GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
GO:0006986111 | Esophagus | ESCC | response to unfolded protein | 107/8552 | 137/18723 | 7.01e-15 | 3.87e-13 | 107 |
GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
GO:000700619 | Esophagus | ESCC | mitochondrial membrane organization | 93/8552 | 116/18723 | 2.16e-14 | 1.11e-12 | 93 |
GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
GO:0035967111 | Esophagus | ESCC | cellular response to topologically incorrect protein | 90/8552 | 116/18723 | 1.94e-12 | 8.11e-11 | 90 |
GO:0010821110 | Esophagus | ESCC | regulation of mitochondrion organization | 107/8552 | 144/18723 | 2.31e-12 | 9.41e-11 | 107 |
GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0421027 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa0521020 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
hsa040689 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa0152110 | Esophagus | ESCC | EGFR tyrosine kinase inhibitor resistance | 55/4205 | 79/8465 | 2.44e-04 | 8.78e-04 | 4.50e-04 | 55 |
hsa042156 | Esophagus | ESCC | Apoptosis - multiple species | 25/4205 | 32/8465 | 9.13e-04 | 2.92e-03 | 1.49e-03 | 25 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0493238 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0421037 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa05210110 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
hsa0406814 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa0152115 | Esophagus | ESCC | EGFR tyrosine kinase inhibitor resistance | 55/4205 | 79/8465 | 2.44e-04 | 8.78e-04 | 4.50e-04 | 55 |
hsa0421511 | Esophagus | ESCC | Apoptosis - multiple species | 25/4205 | 32/8465 | 9.13e-04 | 2.92e-03 | 1.49e-03 | 25 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0493228 | Oral cavity | OSCC | Non-alcoholic fatty liver disease | 124/3704 | 155/8465 | 1.22e-20 | 1.37e-18 | 6.96e-19 | 124 |
hsa0516928 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
hsa0421018 | Oral cavity | OSCC | Apoptosis | 101/3704 | 136/8465 | 3.34e-13 | 7.00e-12 | 3.56e-12 | 101 |
hsa0521018 | Oral cavity | OSCC | Colorectal cancer | 66/3704 | 86/8465 | 3.99e-10 | 4.95e-09 | 2.52e-09 | 66 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BCL2L11 | SNV | Missense_Mutation | novel | c.461G>T | p.Arg154Leu | p.R154L | O43521 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-CN-5355-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
BCL2L11 | SNV | Missense_Mutation | novel | c.425N>A | p.Met142Lys | p.M142K | O43521 | protein_coding | deleterious(0) | benign(0.015) | TCGA-YL-A8SQ-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Hormone Therapy | casodex | SD |
BCL2L11 | SNV | Missense_Mutation | rs146318804 | c.457N>T | p.Arg153Trp | p.R153W | O43521 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B7-A5TI-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | eloxatin | CR |
BCL2L11 | SNV | Missense_Mutation | c.203N>T | p.Ala68Val | p.A68V | O43521 | protein_coding | tolerated(0.53) | benign(0.015) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
BCL2L11 | SNV | Missense_Mutation | novel | c.262C>A | p.Leu88Met | p.L88M | O43521 | protein_coding | deleterious(0.03) | probably_damaging(0.994) | TCGA-HF-A5NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
BCL2L11 | insertion | Frame_Shift_Ins | novel | c.574_575insGCCTG | p.Val194AlafsTer50 | p.V194Afs*50 | O43521 | protein_coding | TCGA-HU-A4GJ-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10018 | BCL2L11 | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TRANSCRIPTION FACTOR | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR | 22426421 | ||
10018 | BCL2L11 | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TRANSCRIPTION FACTOR | imatinib | IMATINIB | 24223824 | |
10018 | BCL2L11 | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TRANSCRIPTION FACTOR | IMATINIB | IMATINIB | 22426421 | |
10018 | BCL2L11 | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TRANSCRIPTION FACTOR | KERACYANIN | KERACYANIN | 17360708 | |
10018 | BCL2L11 | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TRANSCRIPTION FACTOR | corticosteroids | 29282361 |
Page: 1 |